(Q35759170)

10 August 2017

1 reference

title

Ciclosporin in psoriasis clinical practice: an international consensus statement (English)

1 reference

10 August 2017

1 reference

Griffiths CE

1

1 reference

10 August 2017

Dubertret L

2

1 reference

10 August 2017

Ellis CN

3

1 reference

10 August 2017

Finlay AY

4

1 reference

10 August 2017

Finzi AF

5

1 reference

10 August 2017

Ho VC

6

1 reference

10 August 2017

Johnston A

7

1 reference

10 August 2017

Katsambas A

8

1 reference

10 August 2017

Lison AE

9

1 reference

10 August 2017

Naeyaert JM

10

1 reference

10 August 2017

Nakagawa H

11

1 reference

10 August 2017

Paul C

12

1 reference

10 August 2017

Vanaclocha F

13

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

British Journal of Dermatology

10 August 2017

published in

1 reference

10 August 2017

volume

150 Suppl 67

1 reference

10 August 2017

page(s)

11-23

1 reference

Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

The Salford Psoriasis Index: an holistic measure of psoriasis severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Quality of life in 6497 Nordic patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Patients' and doctors' assessment of skin disease handicap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Physical and psychologic measures are necessary to assess overall psoriasis severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Long-term continuous versus intermittent cyclosporin: therapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Malignant tumours and psoriasis: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Potential drug interactions with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

C2 monitoring in maintenance renal transplant recipients: is it worthwhile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Advances in systemic therapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Treatment targeted to cell surface epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Bioequivalence criteria for cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

Long-term safety of cyclosporine in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0366-077X.2004.05949.X

10.1111/J.0366-077X.2004.05949.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference